Oxidized low density lipoprotein enhanced RANKL expression in human osteoblast-like cells. Involvement of ERK, NFkappaB and NFAT  by Mazière, Cécile et al.
Biochimica et Biophysica Acta 1832 (2013) 1756–1764
Contents lists available at SciVerse ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbad isOxidized low density lipoprotein enhanced RANKL expression in human
osteoblast-like cells. Involvement of ERK, NFkappaB and NFATCécile Mazière a,c,d,⁎, Valéry Salle b,c,d, Cathy Gomila a,c,d, Jean-Claude Mazière a,c,d
a Biochemistry Laboratory, South Central Hospital University, René Laennec Avenue, Amiens 80000, France
b Internal Medicine, North Central Hospital University, Place Victor Pauchet, Amiens 80000, France
c INSERM U1088 (EA 4292), University of Picardie-Jules Verne, Amiens, France
d SFR CAP-Santé (FED 4231), Amiens, FranceAbbreviations: RANKL, receptor activator of NFkappaB
nLDL, native LDL; OxLDL, oxidized LDL; CuLDL, Cu2+-ox
SMC-LDL, smooth muscle cell-oxidized LDL; MPO-LD
LDL; ROS, reactive oxygen species; H2O2, hydrogenperoxid
NFAT, nuclear factor of activated T cells
⁎ Corresponding author. Tel.: +33 3 22 08 70 00.
E-mail address: maziere.cecile@chu-amiens.fr (C. M
0925-4439/$ – see front matter © 2013 Elsevier B.V. Al
http://dx.doi.org/10.1016/j.bbadis.2013.05.033a b s t r a c ta r t i c l e i n f oArticle history:
Received 15 March 2013
Received in revised form 29 April 2013
Accepted 31 May 2013
Available online 10 June 2013
Keywords:
Oxidized LDL
RANKL
Oxidative stress
Osteoporosis
Background: Receptor activator of nuclear factor kappa-light-chain-enhancer of activated B cell ligand/
osteoprotegerin ratio is of crucial importance in osteoclast differentiation and thus in bone dysregulation dis-
eases. Methods: Receptor activator of nuclear factor kappa-light-chain-enhancer of activated B cell ligand
and osteoprotegerin were determined under oxidized low density lipoprotein treatment of human
osteoblast-like cells. The involvement of oxidative stress, of the extracellular signal regulated kinase and of
the transcription factors nuclear factor kappa-light-chain-enhancer of activated B cells and nuclear factor of
activated T cells was demonstrated. Results: Cu2+-oxidized low density lipoprotein increased cell-associated
and extracellular receptor activator of nuclear factor kappa-light-chain-enhancer of activated B cell ligand levels
whereas osteoprotegerin levels were not affected. The increase in receptor activator of nuclear factor
kappa-light-chain-enhancer of activated B cell ligand was parallel to the generation of reactive oxygen species
provoked by Cu2+-oxidized low density lipoprotein. The lipid extract of Cu2+-oxidized low density lipoprotein,
together with other forms of oxidized low density lipoproteins such as smoothmuscle cell-oxidized low density
lipoprotein and myeloperoxidase-oxidized low density lipoprotein, also induced an increase in reactive oxygen
species and cell-associated receptor activator of nuclear factor kappa-light-chain-enhancer of activated B cell
ligand. The effect of Cu2+-oxidized low density lipoprotein was prevented by the antioxidant vitamin E,
and mimicked by the prooxidant compounds hydrogen peroxide and buthionine sulfoximine. Inhibitors
of mitogen activated protein kinase/extracellular signal regulated kinase (PD 98059), nuclear factor
kappa-light-chain-enhancer of activated B cells (Ro 106-9920) and nuclear factor of activated T cells
(Vivit) reduced the effect of Cu2+-oxidized low density lipoprotein on receptor activator of nuclear factor
kappa-light-chain-enhancer of activated B cell ligand expression. Cu2+-oxidized low density lipoprotein
signaling was also reduced by vitamin E. General signiﬁcance: This work describes a new molecular
mechanism and elucidates the signaling pathway whereby oxidized low density lipoprotein, by means of
its lipid moiety, can modulate the crosstalk between osteoblasts/osteoclasts and bone remodeling, leading
to an eventual risk of osteoporosis.© 2013 Elsevier B.V. All rights reserved.1. Introduction
Bone remodeling process results from an equilibrium between the
activities of the bone-forming cells called osteoblasts and the bone-
resorbing cells called osteoclasts. This process must be highly regulated
and excessive osteoclast differentiation will lead to pathological bone
diseases such as osteoporosis. The survival and proliferation ofligand; OPG, osteoprotegerin;
idized low density lipoprotein;
L, myeloperoxidase-oxidized
e; BSO, buthionine sulfoximine;
azière).
l rights reserved.osteoclasts are under the control of macrophage-colony stimulating
factor (M-CSF). Besides this cytokine, differentiation of osteoclasts is
also dependent on a cytokine of the tumor necrosis factor (TNF) family
ﬁrst described in activated T cells as a key regulator of T cell-dependent
immune response, and thus termed TNF-related activation-induced
cytokine (TRANCE) [1]. It was further demonstrated that besides its
role in the immune system, this factor, also termed receptor activator
of NFkappaB ligand (RANKL), stimulates osteoclast survival, activation
and differentiation [2,3]. After binding to its receptor RANK localized
at the cell surface of hematopoietic osteoclast precursor cells, RANKL
stimulates their transformation to multinucleated mature osteoclasts.
In addition, it was reported that this osteoclast differentiation factor
is localized at the membrane of osteoblasts/stromal cells [3], and that
osteoblast differentiation is accompanied by the expression of RANKL
1757C. Mazière et al. / Biochimica et Biophysica Acta 1832 (2013) 1756–1764[4]. However, the effect of RANKL is counteracted by osteoprotegerin
(OPG), a soluble decoy receptor also secreted by osteoblasts, which
is an analog of RANK and prevents RANKL binding to its receptor
(Rev in [5]). The RANKL/OPG system is thus of crucial importance in
osteoblast–osteoclast crosstalk and in bone dysregulation diseases; in
this regard, increased RANKL activity has been demonstrated in osteo-
porosis and osteolytic bonemetastasis. In addition, anti-RANKL therapy
has been proposed as a treatment of bone loss [6,7].
Oxidative stress is believed to be at the origin of several degenera-
tive diseases such as atherosclerosis, diabetes, arthritis and aging. Evi-
dence has emerged that oxidative stress is also related to osteoporosis
(Rev in [8]). A decrease in plasma antioxidants was described in aged
osteoporotic women [9], and an increase in oxidative stress is linked
to loss of bone mass in aged men and women [10,11]. Oxidative stress
has been demonstrated to be involved in osteoclast activity in that the0
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Fig. 1. CuLDL increased RANKL level in human osteoblast-like cells. Dose-dependent effec
were treated with 10–50 μg/ml CuLDL protein for 3 days. nLDL: native LDL. 100%: 6 ± 2 a
10 ± 2 pmol/ml and 580 ± 40 nmol/ml for extracellular RANKL and OPG respectively. Resprooxidant hydrogen peroxideH2O2 enhances osteoclast differentiation
and bone resorption inmice [12] and stimulates activation and differen-
tiation of osteoclasts [13]. The role of the RANKL/OPG system in ROS-
mediated osteoclast differentiation was suggested by the fact that
oxidative stress generated by H2O2 and xanthine/xanthine oxidase
stimulates RANKL expression in mouse and human osteoblasts [14].
H2O2 also enhances the expression of M-CSF and RANKL, increases
RANKL/OPG ratio in humanmarrow cells and stimulates their transfor-
mation into osteoclasts [15].
Oxidized LDL (OxLDL) is well known to play an important role
in the generation and progression of atherosclerosis. In addition, it
appeared that cardiovascular disease is often linked to osteoporosis
[16,17]. We reported that many metabolic effects of OxLDL might
be attributed to generation of ROS [18,19]. Concerning the role of
OxLDL on the bone remodeling process, we demonstrated that these0
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t. MG63 cells in a medium supplemented with 2% of fetal calf serum in 6-well plates
nd 340 ± 108 pmol/mg protein for cell-associated RANKL and OPG respectively, and
ults are means from 4 experimental values ± s.d. ***: p b 0.001 by Student's t test.
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Fig. 2. CuLDL increased RANKL level in human osteoblast-like cells. Time-course effect. MG63 cells in a medium supplemented with 2% of fetal calf serum in 6-well plates were
treated with 50 μg/ml CuLDL for 1–3 days. Results are means from 4 experimental values ± s.d. **: p b 0.01; ***: p b 0.001 by Student's t test.
1758 C. Mazière et al. / Biochimica et Biophysica Acta 1832 (2013) 1756–1764particles inhibit phosphate-induced differentiation and mineraliza-
tion of osteoblasts [20], and concomitantly decrease RANKL-induced
differentiation of osteoclast precursors [21]. These effects on bone
turn-over have been attributed to the generation of an oxidative stress
since they were prevented by vitamin E.
In the current studies, we report that Cu2+-oxidized OxLDL
(CuLDL) increases cell-associated and extracellular RANKL in human
osteoblast-like cells. Smooth muscle cells- or myeloperoxidase-
oxidized LDL exhibit a similar effect. This effect is prevented by the
antioxidant vitamin E and reproduced by other oxidants such as H2O2
or buthionine sulfoximine (BSO), an inhibitor of glutathione synthesis.
Finally, by using speciﬁc inhibitors, we identiﬁed ERK, NFkappaB and
NFAT in the signaling pathway of OxLDL.2. Materials and methods
2.1. Cell culture and chemicals
The MG63 human osteosarcoma cell line was purchased from the
European Collection of Cell Cultures (UK) and maintained in EMEM
medium with 10% fetal calf serum FCS from Gibco (Grand Island,
NY, USA). PD 98059, Ro 106-9920 and Vivit were from Calbiochem0
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Fig. 3. CuLDL induced an oxidative stress. (A) Dose-dependent effect. (B) Time-course eff
with 0.5% bovine albumin for 24 h, then treated with 10–50 μg/ml CuLDL for 4 h. (B): Ce
with 25 μg/ml CuLDL protein. Results are means from 3 experimental values ± s.d. *: p b 0(San Diego, CA, USA). Antibodies against ERK and phospho-ERK are
from Cell Signaling, MA, USA. All chemicals were from Sigma-Aldrich.
Treatment with 10–50 μg CuLDL ApoB/ml was performed for
1–3 days in amedium supplementedwith 2% FCS. The prooxidant com-
pounds buthionine sulfoximine (BSO) (10 μM) and H2O2 (0.1 mM)
were added in amedium supplementedwith 2% FCS for 3 days. Vitamin
E, kinase or transcription factor inhibitors were simultaneously added
with CuLDL.
2.2. LDL preparation and oxidation
LDL (d 1.024–1.050) was prepared from normal human serum
by sequential ultracentrifugation according to Havel et al. [22], and
dialysed against 0.005 M Tris, 0.05 M NaCl, and 0.02% EDTA at pH 7.4
for conservation. Prior to oxidation, EDTA was removed by dialysis.
Oxidation with cupric ions was performed by incubation at 37 °C
of 1 mg LDL protein/ml with 5.10–6 M CuSO4 for 48 h. Cellular oxi-
dation of LDL was performed with human coronary artery smooth
muscle cell (HCASMC) primary cultures purchased from Cascade Bio-
logics, Portland, Oregon, USA. 100 μg/ml LDL was incubated for 24 h
with HCASMC in Ham F10 medium supplemented with 0.1% bovine
serum albumin. Oxidation by myeloperoxidase-generated reactive
nitrogen species was conducted as described [23]: 200 μg/ml LDL0
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1759C. Mazière et al. / Biochimica et Biophysica Acta 1832 (2013) 1756–1764was incubated at 37 °C for 8 h in phosphate buffer at pH 7.0 and
containing 100 μM diethylene-triamine-pentaacetic-acid, 0.5 U/ml
myeloperoxidase, 100 μg/ml glucose, 5 kU/ml glucose oxidase and
0.5 mM NaNO2. Oxidation was stopped by the addition of 40 μM
butyl hydroxy toluene and 300 nM catalase, and dialysis against PBS.
The degree of LDL oxidation was checked by relative electrophoretic
mobility, determination of conjugated dienes by absorption at 234 nm,
and determination of lipid peroxidation end products (thiobarbituric
acid reactive substances (TBARS)) by Yagi's method [24]. The lipid
extract of CuLDL was obtained by the method of Bligh and Dyer [25].0
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Fig. 4. SMC-LDL and MPO-LDL increased ROS generation and cell-associated RANKL level. (
SMC-LDL and MPO-LDL. Cells in 12-well plates were preincubated in a medium supplemen
4 h, before determination of ROS. Alternatively, cells in a medium supplemented with 2% F
are means from 3 experimental values ± s.d. **: p b 0.01; ***: p b 0.001 by Student's t test2.3. Determination of RANKL and OPG
Cells were lysed in 50 mM Tris, 50 mM NaF, 20 mM p-nitrophenyl
phosphate, 1 mM EGTA, 0.05 mM Na-vanadate, 5 mM benzamidine
and 1% TX100 for 15 min at 4 °C and sonicated. After centrifugation
at 14,000 g for 2 min, the supernatants were taken as cell lysates.
RANKL and OPG were determined with ELISA kits from Biomedica,
Vienna, Austria. For cell-associated RANKL determination, 30 μg of
cellular proteins was added tomicrowells coated with osteoprotegerin,
a natural RANKL ligand. Extracellular RANKL determination was0
5
10
15
20
25
30
Li
pi
d 
pe
ro
x
id
at
io
n 
pr
o
du
ct
s 
TB
A
R
S
(n
mo
l/m
g A
po
B)
**
***
0
50
100
150
200
250
300
350
Ce
ll-
as
so
ci
at
ed
 R
AN
KL
 (%
 of
 co
nt
ro
l)
cLDL CuLDL SMC-LDL MPO-LDL
MC-LDL MPO-LDL
cLDL CuLDL SMC-LDL MPO-LDL
***
A) Characterization of CuLDL, SMC-LDL and MPO-LDL. (B) Biological effects of CuLDL,
ted with 0.5% bovine albumin for 24 h, then treated with 50 μg/ml OxLDL protein for
CS were treated 3 days with 50 μg/ml OxLDL before determination of RANKL. Results
.
250
300
% 
of
 co
nt
ro
l)
A
****
1760 C. Mazière et al. / Biochimica et Biophysica Acta 1832 (2013) 1756–1764performed after 10× concentration of culture medium. For OPG deter-
mination, 5 μg of proteins was added to microwells coated with OPG
antibodies. After addition of a secondary biotin-conjugated antibody,
the OD was determined at 490 nm with a microplate reader from
Molecular Devices. Results are expressed as percentages of control.
Alternatively, equal amounts of proteins were resolved by SDS-
PAGE, transferred to nitrocellulose membrane, and immunoblotted
with RANKL antibody from R and D, MN, USA. Immunoblots were visu-
alized by enhanced chemiluminescence detection kit from Amersham.0
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chloro-methyl-dichloroﬂuorescein
The increase in ﬂuorescence in living cells in the presence of this
probe allows the determination of reactive oxygen species such as
superoxide anion, hydrogen peroxide and hydroxyl radical [26]. Cells
in 12 well plates were incubated for 15 min with 10-5 M chloro-
methyl-2′7′-dichloroﬂuorescein (Molecular Probes) in phosphate buffer
saline, washed three times with phosphate buffer saline, solubilised in
H2O and sonicated. The ﬂuorescence was determined at 503/529 nm,
normalized on a protein basis and expressed as percentages of control.0
50
100
150
200
250
300A
B
R
ea
ct
iv
e 
O
xy
ge
n
 S
pe
ci
es
(%
 of
 co
nt
ro
l)
0
50
100
150
200
250
300
Ce
ll-
as
so
ci
at
ed
 R
AN
KL
 (%
 of
 co
nt
ro
l)
*** ***
******
0 CuLDL CuLDL LE LE Vit E
Vit E Vit E
0 CuLDL CuLDL LE LE Vit E
Vit E Vit E
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1761C. Mazière et al. / Biochimica et Biophysica Acta 1832 (2013) 1756–17642.5. Intracellular thiol group assay
After incubation with BSO for 24 h, thiol groups were determined
with the ﬂuorescent probe Thiostar (Ann Arbor, MI, USA): cells were
incubated at room temperature for 15 min in DMEM without Phenol
Red supplementedwith 0.1% bovine serum albumin containing 2 μg/ml
Thiostar, then washed, resuspended in H2O and sonicated. The ﬂuores-
cence was determined at 390/510 nm. Results were normalized on a
protein basis and expressed as percentages of control.
2.6. Determination of transcription factor binding activity by ELISA
The nuclear extracts were prepared with the Active Motif kit. Cells
were incubated in hypotonic buffer for 15 min at 4 °C. After centrifu-
gation at 13,000 g for 1 min, the nuclear pellet was resuspended in
lysis buffer and incubated for 30 min at 4 °C. Nuclear extract was
obtained after centrifugation at 13,000 g for 10 min. The transcription
factor binding activities were determined by TransAM ELISA kits
NFkappaB-p65 and NFAT-c1 from Active Motif (Carlsbad, CA, USA).
Brieﬂy, equivalent amounts of nuclear proteins were added to
microwells coated with the consensus oligonucleotide for 1 h at
room temperature. After 3 washes, the primary antibody against the
transcription factor subunit, followed by the second antibody conju-
gated to horse radish peroxidase, was added for 1 h at room temper-
ature. After 4 washes, the developing solution was added for 2 to
10 min at room temperature. The OD was determined at 450 nm with
a microplate reader from Molecular Devices. Results are expressed as
percentages of OD of the control.
3. Results
3.1. CuLDL increased RANKL and ROS levels
We ﬁrst determined cell-associated and extracellular RANKL and
OPG levels by ELISA and found that incubation with 10–50 μg/ml
CuLDL induced a dose-dependent increase in RANKL, whereas OPG
was not affected (Fig. 1). Native LDL exhibited no effect. The augmen-
tation of RANKL was also evidenced by immunoblot, with a some-
what more marked increase for 50 μg/ml CuLDL (×4.7 instead of 2.7
with the ELISA test) (Fig. 1A). A time-course study showed a progres-
sion in the action of CuLDL from 1 to 3 days for cell-associated RANKL
(Fig. 2). Again, the OPG level was not affected. In parallel with
the increase in RANKL, CuLDL induced a dose- and time-dependent
generation of ROS, determined by the ﬂuorescence of the dichloro-
ﬂuorescein probe (Fig. 3).
3.2. SMC- and MPO-oxidized LDL increased RANKL and ROS levels
We then investigate the effects of more physiologically oxidized
LDL, performed by incubation with human smooth muscle cells
or with commercially available myeloperoxidase. Characterization of
these differently oxidized LDL showed that SMC-LDL exhibited the
lowest level of TBARS and variation in relative electrophoretic mobil-
ity (Fig. 4A). MPO-LDL was approximately equivalent to Cu-LDL in
terms of TBARS and electrophoretic mobility. Finally, SMC-LDL and
MPO-LDL exhibited higher levels of conjugated dienes than Cu-LDL.
When tested for their biological effects, SMC- and MPO-modiﬁed
LDL were as efﬁcient as Cu-LDL in increasing ROS generation and
cell-associated RANKL levels (Fig. 4B).
3.3. The effect of CuLDL is mimicked by its lipid extract, by the prooxidant
compounds H2O2 and BSO, and reduced by the antioxidant Vitamin E
To demonstrate the involvement of lipid peroxidation products
included in the CuLDL particle, cells were incubated with its lipid
extract. It was observed that the latter reproduced CuLDL particleaction itself on ROS and cell-associated RANKL (Fig. 5). If the antioxi-
dant vitamin E was simultaneously introduced with CuLDL or its lipid
extract, the stimulatory effects were signiﬁcantly reduced.
In addition, independently of CuLDL, two prooxidant compounds,
hydrogen peroxideH2O2 andBSO (an inhibitor of glutathione synthesis)
both led to a rise in ROS and intracellular RANKL. It is of note that again,
vitamin E inhibited this phenomenon (Fig. 6).
3.4. The MEK/ERK inhibitor PD 98059, NFkappaB inhibitor Ro 106-9920
and NFAT inhibitor Vivit reduced the effect of CuLDL
To elucidate the signaling pathway of CuLDL, we utilized different
kinase and transcription factor inhibitors. Concerning kinases, it was
demonstrated that in this cell line, CuLDL increased ERK phosphoryla-
tion (Fig. 7A), whereas p38 and JNK were not affected (data not
shown). Further, the increase in cell-associated RANKL induced by
CuLDL was inhibited by PD 98059 (Fig. 7B). As for transcription
factors, it was demonstrated that CuLDL stimulated NFkappaB and
NFAT DNA binding activity by about 2-fold (Fig. 8A). Finally, Ro 106
9920 and Vivit both diminished cell-associated RANKL level in the
presence of OxLDL (Fig. 8B).
3.5. The antioxidant vitamin E inhibited CuLDL signaling via ERK,
NFkappaB and NFAT
We ﬁnally tested if the inhibitory effect of vitamin E on CuLDL-
induced ROS generation and RANKL expression (Fig. 5) was related to
CuLDL signaling. It was found that vitamin E reduced CuLDL signaling,
in terms of ERK phosphorylation (Fig. 9A) and NFkappaB or NFAT
DNA binding activities (Fig. 9B).
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We demonstrate in this study that CuLDL increased RANKL
expression and secretion in human osteoblast-like cells, without
affecting its decoy receptor OPG (Figs. 1, 2). This results in an over-
all increase in RANKL/OPG ratio, which is known to promote osteo-
clast differentiation and bone resorption [5]. This effect, together
with the already described inhibition of osteoblast differentiation
by CuLDL [20], is most likely involved in the relationship between
atherosclerosis and osteoporosis [16,17], and points at the fact
that OxLDL, besides its role in cardiovascular disease and inﬂam-
mation, is able to regulate the crosstalk between osteoblasts and
osteoclasts inside bone itself. It is of note that osteoblasts, like vas-
cular cells, have the capacity to oxidize LDL, as reported by Brodeur
et al. [27].
An increase in ROS generation was observed, concomitantly with
the stimulation of RANKL expression (Fig. 3). Furthermore, LDL more
physiologically oxidized by human smooth muscle cells or MPO also
enhanced cell-associated RANKL levels (Fig. 4). Again, in relation
with the degree of LDL oxidation, a parallelism was observed between
ROS generation and cell-associated RANKL level, further showing the
involvement of oxidative stress in CuLDL-induced stimulation of
RANKL expression. The role of the lipid peroxidation products arising
from unsaturated fatty acids included in the CuLDL was demonstratedby the fact that its lipid extract reproduced the effect of the particle
itself (Fig. 5). In addition, the antioxidant vitamin E inhibited the
effects of CuLDL or its lipid extract, in terms of ROS generation and
cell-associated RANKL level. Concerning the mechanism whereby
CuLDL initiated generation of ROS, by using different inhibitors, we
identiﬁed lipoxygenase as the main source in our experimental model
(data not shown).
We further demonstrated that the pro-oxidants H2O2 and BSO also
reproduced CuLDL effects (Fig. 6). The role of ROS in RANKL expres-
sion by the MG63 cell line was reported by Bai et al. [14], but the
action of the OxLDL particles has never been described in osteoblasts.
Indeed, Graham et al. [28] demonstrated that minimally-oxidized LDL
and 8-iso-prostaglandin E2 stimulate RANKL production, but in
another cell type: T lymphocytes from the immune system.
We then investigated the signaling pathway whereby CuLDL stim-
ulated RANKL expression, and pointed at the involvement of the
kinase ERK (Fig. 7), which is in accordance with Bai et al. [14]. Fur-
thermore, it is of note that in our experimental system, besides ERK,
no activation of p38, JNK or PKA by CuLDL was observed (data
not shown). Tao et al. [29] reported that RANKL expression by bone
marrow cells stimulated for differentiation into osteoclasts is inde-
pendent of p38 kinase, whereas Tseng et al. [30] also pointed at the
role of PKA in RANKL expression in another experimental model:
murine aortic cells.
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Fig. 9. Vitamin E reduced the effect of CuLDL-signaling via ERK, NFkappaB and NFAT. Cells were pre-incubated in a medium supplemented with 0.1% bovine serum albumin and
10 μM vitamin E for 24 h, before the addition of 50 μg/ml CuLDL for 1 h. Results are means from 3 experimental values ± s.d. ***: p b 0.001 by Student's t test.
1763C. Mazière et al. / Biochimica et Biophysica Acta 1832 (2013) 1756–1764The CuLDL-induced stimulation of RANKL expression is mediated
by the transcription factors NFkappaB and NFAT (Fig. 7). It can be
noted that in T lymphocytes, the RANKL gene has been shown to
be controlled by NFkappaB [28], and the role of NFATc3 in RANKL
expression in osteoblasts was reported by Lee et al. [31]. Other
known transcription factors which positively regulate RANKL gene
are Cbfa1/Runx2 in mouse primary osteoblasts [32], heat shock fac-
tors (HSFs) in human osteoblasts [14,33], CREB in murine stromal/
osteoblastic cells [34] and ﬁnally STAT3 in ﬁbroblast-like synovial
cells [35]. In accordance with the fact that CuLDL exhibited no effect
on PKA activity, no activation of CREB was evidenced in our experi-
mental model (data not shown), ruling out the hypothesis of a reg-
ulatory effect of PKA. That CuLDL-induced oxidative stress is
involved in ERK, NFkappaB and NFAT activation was demonstrated
by the fact that vitamin E signiﬁcantly prevented this activation
(Fig. 9). It is well known that the NFAT transcription factor is acti-
vated by a rise in intracellular calcium [36], and we checked that
this is the case in our experimental model, by using the ﬂuores-
cent probe Fluo 3. This is in accordance with the previously pub-
lished activation of NFAT by OxLDL-induced oxidative stress by our
group [37].
Our studies demonstrate for the ﬁrst time the stimulatory effect
of OxLDL on RANKL expression in human osteoblast-like cells, and
thus highlight the fact that these particles might up-regulate osteo-
clast differentiation. Ex vivo, Tintut et al. [38] reported that hyper-
lipidaemia promotes the osteoclastic potential of bone marrow
cells in mice. This phenomenon, together with the fact that OxLDL
inhibits differentiation and mineralization of osteoblasts [20], high-
lights the negative effect of these particles in bone formation. In
conclusion, this work points at a new molecular mechanism where-
by OxLDL, via its lipid moiety and by generation of oxidative stress,
might have a negative role in bone remodeling, possibly leading to
osteoporosis. It ﬁnally suggests that lipid lowering therapy might
also have beneﬁts against osteoporosis.Acknowledgements
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